Drugs / YF-17D
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial · 1 met primary | ||||||
| Phase 0 | NCT05468606 | Feb 2023 → Dec 2024 | Plasmodium falciparum malaria | Leiden University Medical Center | Unknown | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03342898 | Feb → May 2018 | dengue disease | Takeda | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05801978 | Apr 2023 → Sep 2027 expected | — | Emory University | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07527247 Background | Nov 2025 → Feb 2029 expected | — | Singapore General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YF17D | “The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial.” NCT05801978 ↗ |
| Known as | YF-VAX | “The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial.” NCT05801978 ↗ |
| Modality | Vaccine | “YF-17D vaccine” NCT03342898 ↗ |
| Route | Subcutaneous | “YF-17D vaccine, 0.5 mL injection, subcutaneously (SC)” NCT03342898 ↗ |